New positron emission tomography (PET) image reconstruction technology has been designed to provide better image quality, reduced acquisition time, and lower injected agent dose.
Present PET iterative reconstruction technologies, such as time-of-flight (TOF) and ordered subset expectation maximization (OSEM), do not have the capability of controlling noise when the number of iterations increases, which leads to a trade-off of quantitative accuracy in favor of image quality.
When deciding whether a particular cancer treatment is effective or not, physicians not only want to identify the tiniest of lesions, but also the capability of determining earlier whether the metabolic activity is being alleviated under the current treatment.
For precise treatment response assessment, a physician needs accurate quantitative applications. General Electric (GE) Healthcare’s GE Healthcare (Chalfont St. Giles, UK) Q.Suite tools exhibit the importance of eliminating variability such as respiratory motion. Q.Suite allows physicians to assess treatment response more accurately than ever before, allowing them to effectively evaluate biologic changes in a patient during and over the course of treatment.
GE Healthcare showcased the Q.Suite T Imaging and Reconstruction tools at the 2013 European Association of Nuclear Medicine Congress (EANM), held October 2013 in Lyon (France). GE Healthcare’s interactive educational experience on PET standardized reconstruction technology presented at the Congress demonstrated what is possible when forcing a choice between image quality or quantitation accuracy is no longer necessary.
PET standardized reconstruction technology that was displayed at EANM interactively shows the potential of full convergence PET imaging.
“We know that cancer patients don’t always respond to their initial course of treatment. If we can give clinicians a more accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working after as few as one to two cycles, saving patient’s unnecessary procedures and a significant amount of money,” said president and CEO of GE Healthcare’s MICT (multiple image computed tomography) business.